Review of the CDRH/CBER Bayesian guidance
On Feb 5, 2010, the US Food and Drug Administration's Center for Devices and Radiological Health issued its Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials. The appearance of this guidance represents another milestone in the agency's efforts to foster innovati...
Saved in:
Published in | Journal of GXP compliance Vol. 14; no. 2; p. 53 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
North Olmsted
UBM LLC
01.04.2010
Informa |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | On Feb 5, 2010, the US Food and Drug Administration's Center for Devices and Radiological Health issued its Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials. The appearance of this guidance represents another milestone in the agency's efforts to foster innovation, science-based development, and knowledge building. Like the Center for Drug Evaluation and Research-sponsored process analytical technology guidance, process validation guidance, and International Conference on Harmonisation guidances before it, this new document is consistent with the agency's efforts to get safe and effective products to market faster. Also, in the spirit of these earlier efforts, it represents a paradigm shift toward a continuous learning approach to planning, monitoring, interpreting, and reporting clinical research. This new guidance grew out of the substantial experience the agency has had with Bayesian methodology in clinical trials. With its probabilistic foundation Bayesian thinking offers greater power and flexibility and provides results in a more natural and intuitive form. |
---|---|
ISSN: | 1552-5791 2150-6590 |